Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Laboratories, Preeclampsia Foundation Partner to ID Genetic Factors of Condition

NEW YORK – Predictive Laboratories, a subsidiary of Predictive Technology Group, said today that it has entered into a research collaboration with the Preeclampsia Foundation to study genetic factors associated with the condition.

Preeclampsia affects 5 percent to 8 percent, or approximately 300,000 pregnancies every year in the US, sometimes causing severe adverse maternal and fetal outcomes, including organ failure, massive blood loss, permanent disability, or even death.

The Preeclampsia Registry is the foundation's patient registry that collects paired medical information and biological samples. Using established Institutional Review Board-approved protocols, Predictive Laboratories and the Preeclampsia Foundation will request samples from more than 2,500 existing and new registry participants for sequencing analysis.

Salt Lake City-based Predictive Laboratories has been granted a period of exclusive access to research data resulting from these new samples enrolled in the Preeclampsia Registry, after which samples and sequencing data will be available to other investigators for future research.

The study is expected to grow the registry, and Predictive Laboratories said it plans to use data from the study to develop a proprietary test for the early detection of women at risk for preeclampsia.